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AbstrAct
Objective Reviews have investigated preparation for 
colonoscopy, but not for surgery, They are also often 
limited to patients up to 16 years, despite many paediatric 
gastroenterologists caring for older patients. We carried 
out a systematic review investigating the optimum bowel 
preparation agents for all indications in children and young 
people.
Design A Cochrane format systematic review of 
randomised controlled trials (RCTs). Data extraction and 
assessment of methodological quality were performed 
independently by two reviewers. Methodological quality 
was assessed using the Cochrane risk of bias tool.
Patients Young people requiring bowel preparation for 
any elective procedure, as defined by the primary studies.
Interventions RCTs comparing bowel preparation with 
placebo or other interventions.
Main outcome measures Adequacy of bowel 
preparation, tolerability and adverse events.
results The search yielded 2124 results and 15 
randomised controlled studies (n=1435)but heterogeneity 
limited synthesis. Meta-analysis of two studies comparing 
polyethylene glycol (PEG) with sodium phosphate showed 
no difference in the quality of bowel preparation (risk ratio 
(RR) 1.27(95% CI 0.66 to 2.44)). Two studies comparing 
sodium picosulfate/magnesium citrate with PEG found no 
difference in bowel preparation but significantly higher 
number of patients needing nasogastric tube insertion 
in the polyethylene glycol-electrolyte lavage solution (RR 
0.04(95% CI 0.01 to 0.18), 45 of 117 in PEG group vs 2 of 
121 in sodium picosulfate group). Meta-analysis of three 
studies (n=241) found no difference between PEG and 
sennasoids (RR 0.73(95% CI 0.31 to 1.71)).
conclusions The evidence base is clinically 
heterogeneous and methodologically at risk of bias. 
There is evidence that all regimens are equally effective. 
However, sodium picosulfate was better tolerated than 
PEG. Future research is needed with all agents and should 
seek to consider safety and tolerability as well as efficacy.
bAckgrOunD
Bowel imaging is a crucial modality in the 
diagnosis and monitoring of inflammatory 
bowel disease, as well as surgery frequently 
being required in such patients. Multiple 
studies have suggested that bowel prepara-
tions must be individually tailored according 
to patient age, size and clinical status.1 
However, currently there is no internationally 
recognised gold standard regimen for paedi-
atric bowel preparations.2 Several regimens 
have been tried with the aim of identifying 
the safest, efficacious and tolerable combina-
tion, with varying success.3
Bowel preparation regimens can be based 
on lavage (bowel clean out) or cathartics 
(agents that accelerates defecation). Exam-
ples include large volume of polyethylene 
glycol-electrolyte lavage solution (PEG-ELS) 
lavage solution, sodium phosphate (an oral, 
low-volume, hyperosmotic agent), sodium 
picosulfate, bisacodyl and dietary measures, 
such as diet packs or clear liquid diets (often 
in combination with other agents).
Adequate bowel preparation prior to such 
procedures is crucial to ensure complete 
visualisation of the colonic mucosa (thus 
successful diagnostic and therapeutic colo-
noscopy, endoscopy and capsule endoscopy) 
What this study hopes to add?
 ► Despite many trials, there is much clinical 
heterogeneity and risk of bias concerns with 
the evidence base, as well as poor safety and 
tolerability reporting.
 ► There is evidence that polyethylene glycol (PEG) 
regimens are effective. However, when compared, 
sodium picosulfate was better tolerated than PEG.
 ► Future research needs to address these key 
methodology issues and also consider safety and 
tolerability as well as efficacy.
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Original article
What is already known on this topic?
 ► Bowel preparation is vital to imaging and surgery in 
young people, but it is key to consider tolerability as 
well as efficacy in these patients.
 ► Previous systematic reviews have only considered 
preparation for imaging and limit the age range, 
despite paediatricians often caring for children until 
older.
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and to minimise the risk of possible contamination 
during surgery. Administration of the agents is much 
more problematic in children compared with adults who 
manage to take the agents readily. In uncooperative chil-
dren, use of a nasogastric tube to administer the agents 
has been reported to be an effective method to guarantee 
bowel wash out.4 Reduced tolerance can result in poor 
outcomes due to inadequate preparation, increased rate 
of complications, extended procedural time and missed 
lesions.3 Additionally, side effects have previously been 
noted, such as hyperphosphataemia, in children who 
receive sodium phosphate.4
While previous reviews have considered preparation 
for colonoscopy,3 they do not always consider surgical 
interventions and often limit their populations at the age 
of 16 years, despite it being normal practice for paedi-
atric gastroenterologists to look after such patients for a 
number of years before transition to adult services.5
We carried out an up-to-date systematic review using 
the Cochrane collaboration format to summarise the 
available evidence investigating the optimum bowel 
preparation agents for all indications in children and 
young people.
MethODs
The objectives of this review were to evaluate the effi-
cacy and safety of different bowel preparation for young 
people for any indication. A full protocol for the study 
was completed by the authors prior to commencement 
of the study and is available on request. This set out the 
procedure for the search, study screening, data extrac-
tion, risk of bias evaluation and analysis.
criteria for considering studies for this review
Randomised controlled trials (RCTs) were included in 
this systematic review. Participants were aged 0–21 years. 
This age range was selected after a scoping search and 
discussion with local stakeholders (tertiary centres) 
confirmed that it can be normal practice in paediatric 
gastroenterology for these patient groups to have vari-
able transition to adult services, but 21 years was agreed 
as an absolute cut-off and reflected several studies 
that would otherwise be excluded. Studies with adults 
included that did not allow analysis of this. Paediatric age 
range was excluded. Studies compared bowel prepara-
tion with another bowel preparation or placebo, with all 
forms and dosing regimens considered. The purpose of 
bowel clearance was for colonoscopy or elective surgery. 
Studies were excluded if the purpose was to treat faecal 
impaction or encopresis. The primary outcome measure 
for the studies was the number of adequate bowel prepa-
rations, as defined by the included studies. Secondary 
outcomes included: tolerability (the proportion of chil-
dren who could take the given therapy without the need 
for support through a nasogastric tube or incomplete 
dosing), duration of procedure, missed lesions due to 
inadequate bowel preparationand occurrence of any 
adverse events.
search methods for identification of studies
Electronic searches (search strategy not limited by 
language) were completed using MEDLINE, The 
Cochrane Central Register of Controlled Trials, Embase 
and CINAHL (inception–15 July 2016) (online supple-
mentary appendix 1). References of included trials were 
also searched. Manufacturers were contacted to identify 
further negative and unpublished research. Abstracts 
were considered for inclusion if full details to judge 
inclusion were offered or available from the authors after 
contact by the study team.
Data extraction and assessment of methodolog-
ical quality of included studies were independently 
performed by two authors, and disagreements were 
solved with involvement of the third author.
Data collection and analysis
All identified abstracts and results from searches were 
reviewed by the authors. If the reference appeared rele-
vant, a full copy of the study was obtained. After reading 
the full texts, each author independently assessed the 
eligibility of all trials identified based on the inclu-
sion criteria above. Disagreement among authors was 
discussed, and agreement was reached by consensus. If 
the data to judge inclusion were unclear, attempts were 
made to contact the authors.
A data extraction form was developed and piloted to 
extract information on relevant features and results of 
all primary and secondary outcomes of included studies. 
The two reviewers separately extracted and recorded data 
on the predefined checklist, with disagreement discussed 
and consensus reached.
The risk of bias of selected trials was assessed inde-
pendently by the authors using the Cochrane risk of bias 
tool with disagreement once again resolved by reaching 
consensus. Study authors were contacted for further 
information when insufficient information was offered 
to judge risk of bias or data were missing for primary 
outcomes. Analysis was completed using Revman (Review 
Manager 5.2, V.5.2.9, The Nordic Cochrane Centre, The 
Cochrane Collaboration, Copenhagen, Denmark, 2012).
The primary outcome—efficacy of bowel prepara-
tion agents—was assessed using the risk ratio (RR) with 
95% CI. The secondary outcomes were assessed by calcu-
lating the RR and 95% CI or the mean difference (MD) 
with 95% CI, as indicated. The authors of included studies 
were again contacted to supply any missing data. Hetero-
geneity among trial results was assessed by inspection of 
graphical presentations and by calculating the χ2 test of 
heterogeneity (a p value of 0.10 was regarded as statisti-
cally significant). We also used the I2 statistic to quantity 
the effect of heterogeneity.6 A result of less than 25% was 
defined as low, up to 75% as moderate and above 75% as 
high heterogeneity. A random-effects model was used, 
with a sensitivity analysis with the fixed-effects model, 
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Figure 1 Patient flow diagram.
to identify differences in results that would suggest 
heterogeneity.
results
The electronic database search identified 2124 studies 
that were screened for inclusion. Of these, 15 studies 
(n=1435) were judged to be potentially relevant and 
subjected to full-text review (figure 1). Only 12 papers 
needed consideration of a third author (less than 1%) 
to reach consensus, with 1 included and 11 excluded. 
Experts were contacted, but no extra reports were 
received and no further studies were identified from 
drug companies.
Description of studies
Excluded studies
Nine reports were excluded for failing to meet the inclu-
sion criteria. Five were not solely with patients under 21 
years of age, three were not RCTs and one was an abstract 
with insufficient data to judge inclusion.
Included studies
The 15 RCTs included described various regimens and 
comparative agents, with nine included in quantita-
tive analysis (table 1) and the remaining six in qualita-
tive analysis (table 2). Four studies compared various 
different regimens and combinations of polyethylene 
glycol (PEG), two compared PEG with oral sodium phos-
phate, two compared PEG with normal saline, three 
compared multiple combinations of PEG, sennasoids 
and sodium picosluphate, two diet kits with sodium phos-
phate, one study compared sodium picosulfate with phos-
phate enemas and one sodium picospulfate with PEG.
risk of bias of included studies
Seven studies were rated as low risk for random sequence 
generation (selection bias) because these studies 
employed computer-generated randomisation. The 
remaining studies described themselves as randomised 
but, with no further details given or available from 
authors, were rated as unclear risk of bias.
Five studies were rated as low risk of bias for allocation 
concealment (selection bias). Nine remaining studies 
were rated as unclear risk of bias for allocation conceal-
ment as the methods were not clearly described in the 
manuscripts. One described the allocated researcher as 
performing colonoscopies and was rated as high risk.
Ten studies were blinded and were judged to be at low 
risk of bias for blinding of personnel (performance bias) 
for such an intervention. Four studies described them-
selves as blinded but gave no further details so was rated 
as unclear risk of bias. One study was open label and 
judged to be at high risk of bias for blinding.
Eight studies reported full and appropriate data and 
satisfactorily documented withdrawals and dropouts and 
were therefore judged to be at low risk of bias for incom-
plete outcome data (attrition bias), and nine were judged 
as low risk for selective reporting (reporting bias). Two 
studies did not record full data for all patients and were 
judged high risk of bias for attrition bias. Four studies did 
not offer outcome data regarding side effects and tolera-
bility so were judged at high risk for reporting bias.
All studies were judged to be at low risk for other 
sources of bias. However, the small sample size of many of 
these studies is concerning, suggesting they were pilot or 
similarly underpowered studies, raising a further concern 
regarding bias. Details are summarised in table 1.
The 15 studies present significant clinical and method-
ological heterogeneity (table 1), and this severely limits 
the scope for synthesis.
Peg versus sennAsOIDs
Meta-analysis of three studies (n=241)7–9 found no differ-
ence between PEG and sennasoids in adequate bowel 
preparation (RR 0.73 (95% CI 0.31 to 1.76), figure 2). 
High statistical heterogeneity was noted. Data regarding 
tolerability and safety were not presented to allow 
synthesis.
sodium picosulfate and magnesium citrate versus Peg-els
Within these two studies versus PEG-ELS,10 11 equiv-
ocal adequacy of bowel preparation was seen (RR 0.99 
(95% CI 0.89 to 1.11), figure 3). PEG’s acceptability 
was reportedly poorer than sodium picosulfate in both 
studies. Meta-analysis of two PEG-ELS studies using 
the random effects model found a significantly higher 
number of patients needing nasogastric tube insertion in 
the PEG-ELS group (45 of 117) than the sodium picosu-
lfate group (2 of 121) (RR 0.04 (95% CI 0.01 to 0.18), 
figure 4).
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One patient in the PEG-ELS group and one in the 
sodium picosulfate group in the two studies were assessed 
as dehydrated and required intravenous fluids. For the 
PEG-ELS patient, a 10-year-old girl is reported who 
required intravenous fluid for 6 hours because of lethargy 
and dehydration (dryness of the oral mucosa and ortho-
static hypotension) with serum electrolyte and glucose 
serum levels within the normal range. For the child in the 
sodium picosulfate group, a 12-year-old girl is reported 
that required intravenous fluids for 2 hours due to mild 
lethargy postprocedure and was discharged well there-
after. Her vital signs were always within normal limits, but 
her serum osmolality was 316 mOsm/L; she had drunk 
only two glasses of apple juice during the entire duration 
of the bowel cleanout. No other serious adverse events 
were noted.
Peg versus nOrMAl sAlIne
Meta-analysis of two studies (n=125) comparing PEG 
with normal saline6 12 found no difference in rate of 
adequate bowel preparation (RR 0.95 (95% CI 0.87 to 
1.04), figure 5). Adverse events were not reported homo-
geneously to allow analysis, but occurred in both groups, 
including abdominal pain and vomiting.
Peg versus sODIuM PhOsPhAte
There were two studies concerning 63 participants.4 13 
Meta-analysis of two studies using the random-effect model 
found no difference in the adequacy of bowel prepara-
tion (RR 1.27 (95% CI 0.66 to 2.45), figure 6). Again, 
high statistical heterogeneity was noted. One of the 
studies needed to insert a nasogastric tube in all patients 
receiving PEG, while in the remaining study, 53% of 
participants in the PEG group were unable to finish 
taking the solution, while all the patients in the sodium 
phosphate group could complete the medication. As 
these were reported differently, no meta-analysis was 
performed. No serious adverse events were reported.
Other stuDIes
Within the remaining studies,1 14–18 no meta-analysis 
was possible. However, no individual study found any 
different in adequacy of bowel preparation or adverse 
events. Tolerability was not well reported across studies. 
While secondary outcome analysis for further items were 
planned, data were not presented to allow this to take 
place.
DIscussIOn
Despite the common requirement for bowel prepara-
tion in young people, the results of this review have 
highlighted a very poor evidence base. A mixture of clin-
ical heterogeneity related to multiple agent regimens 
and methodological heterogeneity limiting the ability 
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Figure 2 Forest plot for PEG versus senna: adequacy of bowel preparation. PEG, polyethylene glycol.
Figure 3 Forest plot for sodium picosulfate and magnesium citrate versus polyethylene glycol-electrolyte lavage solution 
(PEG-ELS): adequacy of bowel preparation.
Figure 4 Forest plot for sodium picosulfate and magnesium citrate versus polyethylene glycol-electrolyte lavage solution 
(PEG-ELS): tolerability of agent.
for meta-analysis has significantly limited synthesis. In 
multiple small analyses, PEG-ELS, senna, normal saline, 
sodium phosphate and sodium picosulfate/magne-
sium citrate found no difference in adequacy of bowel 
preparation. This was similar across the remaining indi-
vidual studies. As such, despite the significant weaknesses 
of the evidence base, it is worth noting that no difference 
in adequacy of bowel preparation has been reported in 
any included study. This was also the case with adverse 
events, although it must be noted these were reported 
in an extremely heterogeneous fashion, with individual 
minor, major and patient overall recording of events 
across studies.
Of note, there was a significant difference in favour 
of sodium picosulfate and magnesium citrate regarding 
tolerability, specifically the need for a nasogastric tube 
to complete the bowel preparation. This is a particularly 
interesting finding, as the primary studies highlighted 
that while tolerability of PEG was extremely poor, smaller 
volumes than planned appeared to have little impact 
on efficacy. This raises the question of the need for 
the nasogastric tube at all and so this may need further 
investigation in the future. Sodium picosulfate was also 
compared with bisacodyl and a phosphate enema in a 
single study with equivocal preparation, tolerability and 
safety reported.
PEG appeared to be the least tolerable agent across all 
studies, with a number of the patients requiring a nasoga-
stric tube insertion, but this is from qualitative synthesis 
of individual studies, with this outcome reported in 
heterogeneous fashion so meta-analysis was not possible. 
Additionally, as the age ranges of included participants 
varied greatly, it is hard to make firm conclusions on this 
finding as the need for nasogastric tubes is likely to be 
very age dependent. Oral sodium phosphate was well 
tolerated in individual studies. Despite the satisfactory 
tolerability and safety profile of sodium phosphate, it 
should be noted that care must be taken when using this 
agent as it can cause significant electrolyte imbalances. 
As such, it should not be used in patients with deranged 
baseline electrolytes, suboptimal renal and hepatic func-
tion, as it poses a risk of acute kidney injury and phos-
phate nephropathy.19
With all the agents studied, the occurrence of minor 
adverse events such as abdominal pain, bloating, faecal 
incontinence, nausea, vomiting, headaches and anal irri-
tation was comparable. No serious adverse events were 
reported in any of the studies. It should also be noted 
that in the context of elective surgery, there is growing 
recognition of the role for proceeding without bowel 
preparation.20
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Figure 5 Forest plot for PEG versus normal saline: adequacy of bowel preparation.
Figure 6 Forest plot for PEG versus sodium phosphate: adequacy of bowel preparation. PEG, polyethylene glycol.
The evidence base for this review covers a large 
number of trials with a reasonable number of patients 
but is severely limited due to clinical and methodolog-
ical heterogeneity, as well as concerns with risk of bias. 
As such, the findings of this review should be inter-
preted with extreme caution as it is difficult to draw firm 
conclusions for any of the investigated agents. It must 
also be noted that, for the primary outcome, successful 
bowel preparation was ‘as defined’' by primary studies, 
with several different scoring systems and criteria used. 
This also limits the appropriateness of meta-analysis in 
this context, although those wishing to complete future 
studies should note the Ottawa scoring system21 was the 
only such scoring method reported in multiple studies. 
This is also true of adverse events, which were reported 
in a sporadic and inconsistent manner that prevented 
comment on even simple complaints, such as nausea or 
vomiting.
Considering the small sample sizes, the high degree 
of heterogeneity and a wide variation in the regimen of 
each cleansing agent, the findings of this review cannot 
be reliably used to inform clinical practise but most 
usefully should inform future research. In particular, 
as the question of adequacy of bowel preparation has 
been established as essentially equivocal among all study 
agents, a shift of focus for future studies is needed. Given 
the unique needs of a paediatric population, considering 
the issue of tolerability as a primary outcome is vital, and 
looking at the lower volume options presented as enteral 
agents could offer potential practical advantages and 
need a high-quality study to investigate them.
cOnclusIOns
The publishing evidence base investigating this issue is 
large but is clinically heterogeneous and at risk of bias. 
All regimens appear equivocal for adequacy of bowel 
preparation. However, when compared with sodium 
picosulfate, sodium picosulfate is better tolerated. Future 
research should seek to consider safety and tolerability, as 
well as efficacy, given the key importance of these issues 
in a childhood population.
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